Engagement Manager, European Thought Leadership, IQVIA
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis. Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.Prior to IQVIA, Aurelio has worked in R&D and in various strategy consulting roles. He holds an MSci in Chemistry from Imperial College London.
Shareholder, McAndrews, Held & Malloy
Senior Vice President of Policy and Strategic Alliances , Association for Accessible Medicines
Craig Burton is the Senior Vice President of Policy and Strategic Alliances for the Association for Accessible Medicines and the Executive Director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups. With more than 20 years of Federal health policy experience, Craig has served in key roles at the center of a range of pressing health care debates. Prior to joining AAM in 2017, Craig was at Avalere Health, where he helped clients anticipate and plan for the impact of change stemming from legislative, regulatory, or other market dynamics. Craig also established and directed the health policy and government relations efforts for two biopharmaceutical companies. Craig served as Deputy Assistant Secretary for Legislation in the U.S. Department of Health and Human Services. In this role, he advised the Secretary, senior Department leaders and White House officials on legislative strategy to achieve key priorities. Craig also served in the Senate, where he was Health Policy Advisor to Senate Majority Leader Bill Frist, M.D., and as professional staff on the U.S. Senate Committee on Health, Education, Labor and Pensions.
Stuart founded Panacea in 2008 after several years of working in the generics arm of the Pharma industry. Panacea provides pharmacovigilance, regulatory affairs and quality assurance services to the industry globally. He has gained experience in board positions of a range of companies over a 30 year career, with particular focus on strategic direction, change management, business development and corporate communication.
Executive Director, Customer Intelligence & Analytics, Pharma Intelligence
Policy & Science Manager, Medicines for Europe
Maja Graf is a Policy & Science Manager at Medicines for Europe and coordinator of Value Added medicines sector group. Maja is pharmacists by training. Before joining Medicines for Europe, she worked in the pharmaceutical industry, working on the off-patent development projects liaising with the external partners across the industry. Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. As a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.
Reporter, Generics Bulletin
Secretary General, International Generic and Biosimilar Medicines Association
Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).
Founder and Managing Director, Birnam Oak Consultancy
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020). Ewan currently works as a consultant to several companies and PE firms advising on corporate strategy including all elements of business development from acquisition to licensing and portfolio selection.
Co-founder and CEO of nucleo (www.go-nucleo.com)
Vice President, Industry Relations, IQVIA
Doug Long is Vice President of Industry Relations at IQVIA (formerly QuintilesIMS) one the world’s largest pharmaceutical information company. IQVIA offers services to the pharmaceutical industry in over 101 countries around the globe. Doug has been with IQVIA since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, and a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.
Associate Partner, Fidelio Healthcare Partners
By education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013. Since 2014 Axel is working as Consultant – mainly but not only in the Pharmaceutical Industry. After some years working as Senior Advisor of Arthur D. Little he joined 2018 Fidelio Healthcare Partners as Associated Partner. In addition, Axel is non-executive member of several supervisory and advisory boards.
Executive Director, The Biosimilars Forum
Juliana (Julie) Reed currently serves as the Executive Director of the Biosimilars Forum, leading strategy for the group’s strategic efforts to increase access to and adoption of biosimilars. Reed served as the Forum’s President for more than eight years and was one of its founders. As the Biosimilars Forum President, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States. She brings more than 30 years of experience in the healthcare sector to the Forum. Most recently, Reed was Vice President and Global Corporate Affairs Lead with Pfizer, specializing in immunology, inflammation and biosimilars portfolios. She also has experience in executive roles leading global corporate and government affairs for Hospira and Coherus BioSciences.
Senior Writer, Generics Bulletin
Managing Director, Ascher Resources
Director General, Medicines for Europe
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Managing Director, Jefferies International
Executive Editor, Generics Bulletin